Genelux Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
24
- Stock Symbol
-
GNLX
- Investments
-
1
- Share Price
-
$2.44
- (As of Friday Closing)
Genelux General Information
Description
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
Contact Information
Website
www.genelux.comCorporate Office
- 2625 Townsgate Road
- Suite 230
- Westlake Village, CA 91361
- United States
Corporate Office
- 2625 Townsgate Road
- Suite 230
- Westlake Village, CA 91361
- United States
Genelux Timeline
Genelux Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.44 | $2.67 | $1.60 - $30.44 | $84.3M | 34.5M | 212K | -$0.96 |
Genelux Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 49,730 | 346,342 | ||
| Revenue | 8 | 170 | 11,068 | 0 |
| EBITDA | (26,432) | (26,701) | (1,731) | (14,066) |
| Net Income | (26,538) | (28,297) | (5,207) | (16,378) |
| Total Assets | 45,179 | 27,893 | 5,531 | 8,126 |
| Total Debt | 2,207 | 2,519 | 26,353 | 25,311 |
Genelux Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Genelux Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Genelux Comparisons
Industry
Financing
Details
0000 0
00000
Genelux Competitors (89)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| ORIC Pharmaceuticals | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000000 | 00000 |
| CureVac | Formerly VC-backed | Tubingen, Germany | 0000 | 00.000 | 00000000 | 00.000 |
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | 000 | 000.00 | 00000000 | 000.00 |
Genelux Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Genelux Patents
Genelux Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4222250-A1 | Bioreactor production of virus from adherent cells | Pending | 02-Oct-2020 | 00000000 | |
| JP-2023544184-A | Bioreactor generation of viruses from adherent cells | Pending | 02-Oct-2020 | 00000000 | |
| US-10851350-B1 | Bioreactor production of virus from adherent cells | Active | 27-Jun-2017 | 00000000 | 00 |
| US-20230233631-A1 | Methods for combining adoptive t cell therapy with oncolytic virus adjunct therapy | Pending | 09-Sep-2015 | 0000000000 | 0 |
| US-20160339066-A1 | Oncolytic virus adjunct therapy with agents that increase virus infectivity | Active | 02-Jan-2014 | A61K35/768 |
Genelux Executive Team (10)
| Name | Title | Board Seat |
|---|---|---|
| Thomas Zindrick JD | Chief Executive Officer & Chairman | |
| Lourie Zak | Chief Financial Officer | |
| Joseph Cappello Ph.D | Chief Technical Officer | |
| Ralph Smalling | Executive | |
| Tony Yu Ph.D | Senior Vice President |
Genelux Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| James Tyree | Self | Lead Independent Director | 000 0000 |
| John Smither | Self | Board Member | 000 0000 |
| John Thomas Ph.D | Imperative (Pasadena) | Board Member | 000 0000 |
| Mary Mirabelli | Self | Board Member | 000 0000 |
| Thomas Zindrick JD | Genelux | Chief Executive Officer & Chairman | 000 0000 |
Genelux Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Genelux Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| V2ACT Therapeutics | 01-Jan-2019 | 00000 0000 | Drug Discovery |
Genelux ESG
Risk Overview
Risk Rating
Updated March, 19, 2024
31.44 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 446
Rank
Percentile
Genelux FAQs
-
When was Genelux founded?
Genelux was founded in 2001.
-
Who is the founder of Genelux?
Aladar Szalay is the founder of Genelux.
-
Who is the CEO of Genelux?
Thomas Zindrick JD is the CEO of Genelux.
-
Where is Genelux headquartered?
Genelux is headquartered in Westlake Village, CA.
-
What is the size of Genelux?
Genelux has 24 total employees.
-
What industry is Genelux in?
Genelux’s primary industry is Drug Discovery.
-
Is Genelux a private or public company?
Genelux is a Public company.
-
What is Genelux’s stock symbol?
The ticker symbol for Genelux is GNLX.
-
What is the current stock price of Genelux?
As of 13-Sep-2024 the stock price of Genelux is $2.44.
-
What is the current market cap of Genelux?
The current market capitalization of Genelux is $84.3M.
-
What is Genelux’s current revenue?
The trailing twelve month revenue for Genelux is $8K.
-
Who are Genelux’s competitors?
Aura Biosciences, Sutro Biopharma, ORIC Pharmaceuticals, CureVac, and Inovio Pharmaceuticals are some of the 89 competitors of Genelux.
-
What is Genelux’s annual earnings per share (EPS)?
Genelux’s EPS for 12 months was -$0.96.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
